HC Wainwright & Co. reiterates Buy rating on Sol-Gel Technologies, $110 price target

Sol-Gel Technologies Ltd. (SLGL) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 Sol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate Updates • Pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome remains ongoing, with top-line results on track for anticipated readout in late November 2026 • So

Citius Oncology presented data at the EORTC-CLTG 2026 Annual Meeting showing that 13 of 41 patients with cutaneous T-cell lymphoma (CTCL) experienced reduced itching for at least four weeks after treatment with LYMPHIR. The study also reported sustained improvements in skin-related and overall quality of life for responders. Citius Oncology's CEO and CMO highlighted the importance of these findings for patient well-being and treatment choices.

Citius Oncology (CTOR) presented positive quality of life data for LYMPHIR in relapsed or refractory cutaneous T-cell lymphoma (CTCL) at the EORTC-CLTG 2026 Annual Meeting. Patients reported sustained improvements in skin-related quality of life and pruritus. The company also announced a partnership for a Quality of Life Workshop in November 2026.

Barclays raised its price target for DuPont de Nemours to $176 from $156, citing a 14.7% upside from the Nov 3 close. Other recent targets range from $145 to $162. Barclays maintains an Overweight rating.

Riot Platforms (RIOT) announced a 15-year lease with a leading AI lab for its Corsicana campus, totaling 910 MW. This deal, along with others, brings RIOT's contracted data center revenue to $3.8B. The company expects $2.2B in average annual net operating income. RIOT has reduced its Bitcoin holdings and repaid a $200M credit facility, ending Q3 with $950M in liquidity.

Morgan Stanley kept Duolingo at Equal-Weight but raised its price target to $145 from $140, suggesting a 13.3% upside from the Nov 3 close of $128. Recent analyst targets for Duolingo range from $120 to $165.